Full Text View
Tabular View
No Study Results Posted
Related Studies
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
This study is ongoing, but not recruiting participants.
Study NCT00586443   Information provided by Duke University

First Received on December 21, 2007.   Last Updated on April 4, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Solid Tumors
Additional conditions recognized in this trial
Neoplasms
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Bevacizumab
Everolimus
Sirolimus
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Herbert Hurwitz
Novartis
Genentech
Amgen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services